Pain News and Research

Latest Pain News and Research

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Vascular surgeries provide relief from two debilitating conditions

Vascular surgeries provide relief from two debilitating conditions

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

US patients undergoing orthopaedic surgery receive more treatments for pain

US patients undergoing orthopaedic surgery receive more treatments for pain

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

BioDelivery Sciences calls for new treatment options for opioid addiction

BioDelivery Sciences calls for new treatment options for opioid addiction

2015 EuroHeartCare annual meeting to highlight recent advances in cardiovascular nursing research, practice

2015 EuroHeartCare annual meeting to highlight recent advances in cardiovascular nursing research, practice

Tennessee physician offers innovative painless procedure for postmenopausal patients

Tennessee physician offers innovative painless procedure for postmenopausal patients

Acupuncture-like TENS may be effective for treating radiation-induced xerostomia

Acupuncture-like TENS may be effective for treating radiation-induced xerostomia

Fair Rate Funding: Delaware woman gets $100M against Boston Scientific in TV mesh judgment

Fair Rate Funding: Delaware woman gets $100M against Boston Scientific in TV mesh judgment

People with cognitive impairment have altered responses to pain

People with cognitive impairment have altered responses to pain

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.